The Loughborough, England–based company’s SugarBeat is a non-invasive and flexible CGM designed to pair with BeatDiabetes, the company’s planned health subscription service for people with Type 2 diabetes and prediabetes. Nemaura Medical plans to launch the BeatDiabetes subscription service with personalized lifestyle coaching next month.
Nemaura Medical won CE Mark approval for SugarBeat last year and supplied devices to a limited cohort of users as it scaled up its manufacturing operations, according to a news release. In July 2019, Nemaura submitted a De Novo medical device applications to the FDA for SugarBeat.
The company plans to conduct a user study comparing SugarBeat directly against a successful incumbent CGM sensor with the goal of positioning SugarBeat as a non-invasive, daily/flexible, cost-effective alternative to traditionally expensive and invasive CGM sensors.
“We believe that the launch of our app is a big step towards our commercial milestones, and we are looking forward to launching the BeatDiabetes subscription service shortly during Type 2 Diabetes Prevention Week in the UK,” Nemaura CEO Dr. Faz Chowdhury said in the news release. “The SugarBeat app includes time-in-range profiling features which we believe is rapidly being adopted as the primary metric for managing individual daily blood glucose profiles”.